Structural and functional characterization of a specific antidote for ticagrelor. - Wikidata - wikimedia - TriplyDB

Structural and functional characterization of a specific antidote for ticagrelor.

Structural and functional characterization of a specific antidote for ticagrelor.

http://www.wikidata.org/entity/Q41194895

about

Ticagrelor: Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Profile: An Update Impact of Timing on the Functional Recovery Achieved With Platelet Supplementation After Treatment With Ticagrelor.Long-term antiplatelet therapy following myocardial infarction: implications of PEGASUS-TIMI 54.Oral antiplatelet therapy: impact for transfusion medicine.Safety of Antithrombotic Agents in Elderly Patients with Acute Coronary Syndromes.New directions for pharmacotherapy in the treatment of acute coronary syndrome.Platelet inhibition and bleeding complications in cardiac surgery: A review.Effects of autologous platelet transfusion on platelet inhibition in ticagrelor-treated and clopidogrel-treated subjects.Unraveling the pharmacokinetic interaction of ticagrelor and MEDI2452 (Ticagrelor antidote) by mathematical modeling.Consensus Document of the Italian Association of Hospital Cardiologists (ANMCO), Italian Society of Cardiology (SIC), Italian Association of Interventional Cardiology (SICI-GISE) and Italian Society of Cardiac Surgery (SICCH): clinical approach to p Modeling Membrane Protein-Ligand Binding Interactions: The Human Purinergic Platelet Receptor.Hemostatic effects of the ticagrelor antidote MEDI2452 in pigs treated with ticagrelor on a background of aspirin.Management of anticoagulation in hip fractures: A pragmatic approach.eComment. Rise of Ticagrelor and the vital necessity for specific reversal agents.Quantification of unbound concentration of ticagrelor in plasma as a proof of mechanism biomarker of the reversal agent, MEDI2452

P2860

Q27006031-2D1C180E-78C5-4A19-9DA6-82CFADDD7F58 Q38372841-6A9FCA21-F0CF-4A99-B681-A0A6584A4113 Q38726573-EDE5FE3D-BD6B-4AB0-8719-D3D58721544D Q38754884-7E56D901-81CA-4842-87C2-BD9F82BA0FB8 Q38760067-C333C36B-933C-43A5-8FD3-844C160888E8 Q38817144-7A2CD7D1-ECC1-4319-9621-71E22134F8F6 Q38945083-0EB7C21D-5CCB-435B-A04E-C01BB19CED24 Q39366233-D5FC82DF-3C3B-4483-BBDF-89DB38408E4B Q39678483-88E7FC40-C909-47AC-8E01-88B0803E1441 Q41082977-DC220C0A-F0CF-436C-A204-6D60E0278F5C Q42079428-4EBB0393-C816-4A4B-9E30-DBCC6B44C54B Q50786662-4F357D5D-C814-4BBF-88F8-2B67DCFE35A7 Q51788589-4220C2C7-1B15-45C2-B899-8704F87A9EF8 Q54318711-865CC0BD-83C4-4F8F-AD7A-00BFC8A0B2CF Q57174610-5CCDE3BA-27F2-40AA-924F-6B72E711D8F9

P2860

Structural and functional characterization of a specific antidote for ticagrelor.

http://www.wikidata.org/entity/Q41194895

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Structural and functional characterization of a specific antidote for ticagrelor.

@en

type

label

Structural and functional characterization of a specific antidote for ticagrelor.

@en

prefLabel

Structural and functional characterization of a specific antidote for ticagrelor.

@en

P1433

Q41194895-E74EE69B-1EBD-47C9-9477-3BDF8B78E6BB

P1476

Q41194895-5CCF7E56-9C37-45E9-A427-BDD39B7C55FB

P2093

Q41194895-1D65B891-F482-440C-97C5-263D3752E89B

Q41194895-26D32699-A8B2-461B-9722-C7979C9B7B90

Q41194895-27446568-3581-4E53-AA02-8A4580C5CEEB

Q41194895-35B5C2A7-1843-4F9B-B48E-E95DDE21AFF6

Q41194895-4AE6D39D-9901-410A-AA15-938C3C9752A7

Q41194895-5D211103-50D7-494A-90BB-D97AA828E0DE

Q41194895-61C608E3-6D71-49FB-AA6C-5F16EEDF470E

Q41194895-799546E3-1965-43E6-8A3B-DF2865735D43

Q41194895-8393E2BD-78DC-4F08-9E10-2D638C095D3B

Q41194895-946A932D-5C3B-4DD2-B413-50081415EA79

P2860

Q41194895-02A0BB94-1E04-4B1C-B156-FF2EE45CD49F

Q41194895-04945E69-4FD0-4F3E-A4A3-B470F0EA261E

Q41194895-0F5C1549-AC5B-4187-9412-4F786E444826

Q41194895-18DDFEDC-05E8-4B10-9EDA-D4D5840B4FDC

Q41194895-2E451197-84FC-4A6B-A534-4AD60D726998

Q41194895-72DA5EB9-101F-4086-9469-307F5A7D795A

Q41194895-7D5D4254-1037-4C52-9F12-539874122B77

Q41194895-840EC751-4EFB-4B5F-B5BD-8D690D8A18EC

Q41194895-9F165E54-FEB4-49DE-B2A7-E3D980807C46

Q41194895-B32AC7B6-54F3-45C1-8CCB-A3E355086A91

P304

Q41194895-A52466C9-D161-427B-8724-8C96053508F2

P31

Q41194895-6458B480-D4FA-400E-8504-17B2207D3D87

P356

Q41194895-3BB4C3DC-15A9-40EA-9DA2-1FB6F967D13F

P407

Q41194895-1F4473BD-166A-4E52-8DB9-96E57CEB9AEB

P433

Q41194895-930BD187-ACD6-42B4-9E44-36C66557056B

P478

Q41194895-181B01D6-3225-407D-9E0E-54AA45812356

P577

Q41194895-26E199E9-76EB-4065-A6E8-8E06E47E6A5A

P698

Q41194895-953C7B25-B245-46AA-8F6A-7F3AF881515B

P932

Q41194895-39B9AEA3-DAF7-4256-B677-BA7EE05BE114

P356

BLOOD-2015-01-622928

P1433

P1476

Structural and functional characterization of a specific antidote for ticagrelor.

@en

P2093

Andrew Buchanan

http://www.w3.org/2001/XMLSchema#string

Ann-Sofie Sandinge

http://www.w3.org/2001/XMLSchema#string

Annika Janefeldt

http://www.w3.org/2001/XMLSchema#string

Feenagh Keyes

http://www.w3.org/2001/XMLSchema#string

Garnet Howells

http://www.w3.org/2001/XMLSchema#string

Jennifer Spooner

http://www.w3.org/2001/XMLSchema#string

Linda Öster

http://www.w3.org/2001/XMLSchema#string

Mark Austin

http://www.w3.org/2001/XMLSchema#string

Mark Penney

http://www.w3.org/2001/XMLSchema#string

Peder Svensson

http://www.w3.org/2001/XMLSchema#string

P2860

ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC)

An anti-hapten camelid antibody reveals a cryptic binding site with significant energetic contributions from a nonhypervariable loop

Structure of the human P2Y12 receptor in complex with an antithrombotic drug

A specific antidote for dabigatran: functional and structural characterization

2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

Ticagrelor versus clopidogrel in patients with acute coronary syndromes

Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects.

A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa

Associating Drugs, Targets and Clinical Outcomes into an Integrated Network Affords a New Platform for Computer-Aided Drug Repurposing.

Adenosine-mediated effects of ticagrelor: evidence and potential clinical relevance.

P304

3484-3490

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2015-01-622928

http://www.w3.org/2001/XMLSchema#string

P407

P433

22

http://www.w3.org/2001/XMLSchema#string

P478

125

http://www.w3.org/2001/XMLSchema#string

P577

2015-03-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25788700

http://www.w3.org/2001/XMLSchema#string

P932

4447862

http://www.w3.org/2001/XMLSchema#string